Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update

Current Medicinal Chemistry

Volumn 16, Issue 22, 2009, Pages 2876-2889

  Zhan, Peng ^a   Liu, Xinyong ^a   Li, Zhenyu ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

AIDS; Drug design; Drug resistance; HIV; Inhibitor; NNRTIs

Indexed keywords

3,4 DIHYDRO 2 ALKOXY 6 BENZYL 4 OXYPYRIMIDINE DERIVATIVE; AG 15549; ANILINYLBENZYL OXADIAZOLE DERIVATIVE; ANILINYLBENZYL OXAZOLE DERIVATIVE; ARYLTETRAZOLYACETANILIDE DERIVATIVE; BENZIMIDAXOLONE DERIVATIVE; BENZOPHENONE DERIVATIVE; CAPRAVIRINE; DIARYL ETHER PYRAZOLE DERIVATIVE; DIARYLAMINE DERIVATIVE; GW 678248; MK 4965; N ARYL PYRROLIDINONE DERIVATIVE; OXINDOLE; QUINOLONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFANYLTRIAZOLE DERIVATIVE; TRIAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR MODEL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 70349395798     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788803231     Document Type: Review

References (68)

1. AIDS Epidemic Update: December 2007. Joint United Nations Programme on HIV/AIDS and World Health Organization 2007.
2. Martins, S.; Ramos, M.J.; Fernandes, P.A. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr. Med. Chem., 2008, 15, 1083-95
3. Campiani, G.; Ramunno, A.; Maga, G.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Morelli, E.; Novellino, E. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives. Curr. Pharm. Des., 2002, 8, 615-57.
4. Boone, L.R. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Opin. Investig. Drugs, 2006, 7, 128-35.
5. El, S.-Y.; Vivet-Boudou, V.; Marquet, R. HIV-1 reverse transcriptase inhibitors. Appl. Microbiol. Biotechnol., 2007, 75, 723-37.
6. Ilina, T.; Parniak, M.A. Inhibitors of HIV-1 reverse transcriptase. Adv. Pharmacol., 2008, 56, 121-67
7. Jochmans, D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res., 2008, 134, 171-85.
8. Sweeney, Z.K.; Klumpp, K. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: The development pipeline and recent clinical data. Curr. Opin. Drug Discov. Devel., 2008, 11, 458-70.
9. Sarafianos, S.G.; Das, K.; Hughes, S.H.; Arnold, E. Taking aim at a moving target: Designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr. Opin. Struct. Biol., 2004, 14, 716-30.
10. Tucker, T.J.; Saggar, S.; Sisko, J.T.; Tynebor, R.M.; Williams, T.M.; Felock, P.J.; Flynn, J.A.; Lai, M.T.; Liang, Y.; McGaughey, G.; Liu, M.; Miller, M.; Moyer, G.; Munshi, V.; Perlow-Poehnelt, R.; Prasad, S.; Sanchez, R.; Torrent, M.; Vacca, J.P.; Wan, B.L.; Yan, Y. The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations. Bioorg. Med. Chem. Lett., 2008, 18, 2959-66.
11. Tucker, T.J.; Sisko, J.T.; Tynebor, R.M.; Williams, T.M.; Felock, P.J.; Flynn, J.A.; Lai, M.T.; Liang, Y.; McGaughey, G.; Liu, M.; Miller, M.; Moyer, G.; Munshi, V.; Perlow-Poehnelt, R.; Prasad, S.; Reid, J.C.; Sanchez, R.; Torrent, M.; Vacca, J.P.; Wan, B.L.; Yan, Y. Discovery of 3-{5-[(6-Amino-1H-pyrazolo [3,4-b]pyridine-3-yl) methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J. Med. Chem., 2008, 51, 6503-11.
12. Lai, M.T.; Munshi, V.; Touch, S.; Tynebor, R.M.; Tucker, T.J.; McKenna, P.M.; Williams, T.M.; Distefano, D.J.; Hazuda, D.J.; Miller, M.D. Antiviral activity of MK-4965: A novel nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother., 2009 Mar 16. (Epub ahead of print).
13. Sweeney, Z.K.; Harris, S.F.; Arora, N.; Javanbakht, H.; Li, Y.; Fretland, J.; Davidson, J.P.; Billedeau, J.R.; Gleason, S.K.; Hirschfeld, D.; Kennedy-Smith, J.J.; Mirzadegan, T.; Roetz, R.; Smith, M.; Sperry, S.; Suh, J.M.; Wu, J.; Tsing, S.; Villasen..or, A.G.; Paul, A.; Su, G.; Heilek, G.; Hang, J.Q.; Zhou, A.S.; Jernelius, J.A.; Zhang, F.J.; Klumpp, K. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. J. Med. Chem., 2008, Nov 14. [Epub ahead of print]
14. Sweeney, Z.K.; Dunn, J.P.; Li, Y.; Heilek, G.; Dunten, P.; Elworthy, T.R.; Han, X.; Harris, S.F.; Hirschfeld, D.R.; Hogg, J.H.; Huber, W.; Kaiser, A.C.; Kertesz, D.J.; Kim, W.; Mirzadegan, T.; Roepel, M.G.; Saito, Y.D.; Silva, T.M.; Swallow, S.; Tracy, J.L.; Villasenor, A.; Vora, H.; Zhou, A.S.; Klumpp, K. Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett., 2008, 18, 4352-4.
15. Elworthy, T.R.; Dunn, J.P.; Hogg, J.H.; Lam, G.; Saito, Y.D.; Silva, T.M.; Stefanidis, D.; Woroniecki, W.; Zhornisky, E.; Zhou, A.S.; Klumpp, K. Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett., 2008, 18, 6344-7.
16. Sweeney, Z.K.; Acharya, S.; Briggs, A.; Dunn, J.P.; Elworthy, T.R.; Fretland, J.; Giannetti, A.M.; Heilek, G.; Li, Y.; Kaiser, A.C.; Martin, M.; Saito, Y.D.; Smith, M.; Suh, J.M.; Swallow, S.; Wu, J.; Hang, J.Q.; Zhou, A.S.; Klumpp, K. Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase. Bioorg. Med. Chem. Lett., 2008, 18, 4348-51.
17. Sweeney, Z.K.; Kennedy-Smith, J.J.; Wu, J.; Arora, N.; Billedeau, J.R.; Davidson, J.P.; Fretland, J.; Hang, J.Q.; Heilek, G.M.; Harris, S.F.; Hirschfeld, D.; Inbar, P.; Javanbakht, H.; Jernelius, J.A.; Jin, Q.; Li, Y.; Liang, W.; Roetz, R.; Sarma, K.; Smith, M.; Stefanidis, D.; Su, G.; Suh, J.M.; Villaseñor, A.G.; Welch, M.; Zhang, F.J.; Klumpp, K. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties. ChemMedChem, 2008, 4, 88-99.
18. Wu, B.; Kuhen, K.; Ngoc Nguyen, T.; Ellis, D.; Anaclerio, B.; He, X.; Yang, K.; Karanewsky, D.; Yi, H.; Wolff, K.; Bieza, K.; Caldwell, J.; He, Y. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1. Bioorg. Med. Chem. Lett., 2006, 16, 3430-3.
19. Wyatt, P.G.; Bethell, R.C.; Cammack, N.; Charon, D.; Dodic, N.; Dumaitre, B.; Evans, D.N.; Green, D.V.; Hopewell, P.L.; Humber, D.C.; et al. Benzophenone derivatives: A novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. J. Med. Chem., 1995, 38, 1657-65
20. Chan, J.H.; Freeman, G.A.; Tidwell, J.H.; Romines, K.R.; Schaller, L.T.; Cowan, J.R.; Gonzales, S.S.; Lowell, G.S.; Andrews, C.W.3rd.; Reynolds, D.J.; St Clair, M.; Hazen, R.J.; Ferris, R.G.; Creech, K.L.; Roberts, G.B.; Short, S.A.; Weaver, K.; Koszalka, G.W.; Boone, L.R. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem., 2004, 47, 1175-82.
21. Ferris, R.G.; Hazen, R.J.; Roberts, G.B.; St Clair, M.H.; Chan, J.H.; Romines, K.R.; Freeman, G.A.; Tidwell, J.H.; Schaller, L.T.; Cowan, J.R.; Short, S.A.; Weaver, K.L.; Selleseth, D.W.; Moniri, K.R.; Boone, L.R. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother., 2005, 49, 4046-51.
22. Hazen, R.J.; Harvey, R.J.; St Clair, M.H.; Ferris, R.G.; Freeman, G.A.; Tidwell, J.H.; Schaller, L.T.; Cowan, J.R.; Short, S.A.; Romines, K.R.; Chan, J.H.; Boone, L.R. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob. Agents Chemother., 2005, 49, 4465-73.
23. Romines, K.R.; Freeman, G.A.; Schaller, L.T.; Cowan, J.R.; Gonzales, S.S.; Tidwell, J.H.; Andrews, C.W.3rd.; Stammers, D.K.; Hazen, R.J.; Ferris, R.G.; Short, S.A.; Chan, J.H.; Boone, L.R. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J. Med. Chem., 2006, 49, 727-39.
24. Ren, J.; Chamberlain, P.P.; Stamp, A.; Short, S.A.; Weaver, K.L.; Romines, K.R.; Hazen, R.; Freeman, A.; Ferris, R.G.; Andrews, C.W.; Boone, L.; Chan, J.H.; Stammers, D.K. Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem., 2008, 51, 5000-8.
25. Jiang, T.; Kuhen, K.L.; Wolff, K.; Yin, H.; Bieza, K.; Caldwell, J.; Bursulaya, B.; Wu, T.Y.; He, Y. Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I. Bioorg. Med. Chem. Lett., 2006, 16, 2105-8.
26. Jiang, T.; Kuhen, K.L.; Wolff, K.; Yin, H.; Bieza, K.; Caldwell, J.; Bursulaya, B.; Tuntland, T.; Zhang, K.; Karanewsky, D.; He, Y. Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2. Bioorg. Med. Chem. Lett., 2006, 16, 2109-12.
27. Ellis, D.; Kuhen, K.L.; Anaclerio, B.; Wu, B.; Wolff, K.; Yin, H.; Bursulaya, B.; Caldwell, J.; Karanewsky, D.; He, Y. Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 4246-51.
28. Wang, Z.; Wu, B.; Kuhen, K.L.; Bursulaya, B.; Nguyen, T.N.; Nguyen, D.G.; He, Y. Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med.Chem.Lett,. 2006, 16, 4174-7.
29. De La Rosa, M.; Kim, H.W.; Gunic, E.; Jenket, C.; Boyle, U.; Koh, Y.H.; Korboukh, I.; Allan, M.; Zhang, W.; Chen, H.; Xu, W.; Nilar, S.; Yao, N.; Hamatake, R.; Lang, S.A.; Hong, Z.; Zhang, Z.; Girardet, J.L. Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett., 2006, 16, 4444-9.
30. Zhang, Z.; Xu, W.; Koh, Y.H.; Shim, J.H.; Girardet, J.L.; Yeh, L.T.; Hamatake, R.K.; Hong, Z. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents. Chemother., 2007, 51, 429-37.
31. Muraglia, E.; Kinzel, O.D.; Laufer, R.; Miller, M.D.; Moyer, G.; Munshi, V.; Orvieto, F.; Palumbi, M.C.; Pescatore, G.; Rowley, M.; Williams, P.D.; Summa, V. Tetrazole thioacetanilides: Potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Bioorg. Med. Chem. Lett., 2006, 16, 2748-52.
32. O'Meara, J.A.; Jakalian, A.; LaPlante, S.; Bonneau, P.R.; Coulombe, R.; Faucher, A.M.; Guse, I.; Landry, S.; Racine, J.; Simoneau, B.; Thavonekham, B.; Yoakim, C. Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 3362-6.
33. Gagnon, A.; Amad, M.H.; Bonneau, P.R.; Coulombe, R.; DeRoy, P.L.; Doyon, L.; Duan, J.; Garneau, M.; Guse, I.; Jakalian, A.; Jolicoeur, E.; Landry, S.; Malenfant, E.; Simoneau, B.; Yoakim, C. Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases. Bioorg. Med. Chem. Lett., 2007, 17, 4437-41.
34. Zhan, P.; Li, Z.; Liu, X.; De Clercq, E. Sulfanyltriazole/tetrazoles: A promising class of HIV-1 NNRTIs. Mini. Rev. Med. Chem., 2009, 9, in proof.
35. Zhan, P.; Liu, X.; Cao, Y.; Wang, Y.; Pannecouque, C.; De Clercq, E. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 5368-71.
36. Gewurz, B.E.; Jacobs, M.; Proper, J.A.; Dahl, T.A.; Fujiwara, T.; Dezube, B.J. Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: A phase 1 study. J. Infect. Dis., 2004, 190, 1957-61.
37. Sato, A.; Hammond, J.; Alexander, T.N.; Graham, J.P.; Binford, S.; Sugita, K.; Sugimoto, H.; Fujiwara, T.; Patick, A.K. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res., 2006, 70, 66-74.
38. Di Santo, R.; Costi, R.; Artico, M.; Miele, G.; Lavecchia, A.; Novellino, E.; Bergamini, A.; Cancio, R.; Maga, G. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: Synthesis, structure-activity relationships, and docking studies (part 1). ChemMedChem, 2006, 1, 1367-78
39. Lavecchia, A.; Costi, R.; Artico, M.; Miele, G.; Novellino, E.; Bergamini, A.; Crespan, E.; Maga, G.; Di Santo, R. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: Synthesis, structure-activity relationships, and docking studies (part 2). ChemMedChem, 2006, 1, 1379-90
40. Jones, L.H.; Dupont, T.; Mowbray, C.E.; Newman, S.D. A concise and selective synthesis of novel 5-aryloxyimidazole NNRTIs. Org. Lett., 2006, 8, 1725-7.
41. Jones, L.H.; Allan, G.; Corbau, R.; Hay, D.; Middleton, D.S.; Mowbray, C.E.; Newman, S.D.; Perros, M.; Randall, A.; Vuong, H.; Webster, R.; Westby, M.; Williams, D. Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors. ChemMedChem, 2008, 3, 1756-62.
42. Reddy, M.R.; Erion, M.D. Relative binding affinities of fructose- 1,6-bisphosphatase inhibitors calculated using a quantum mechanics-based free energy perturbation method. J. Am. Chem. Soc., 2007, 129, 9296-7.
43. Park, H.; Lee, S. Free energy perturbation approach to the critical assessment of selective cyclooxygenase-2 inhibitors. J. Comput. Aided Mol. Des., 2005, 19, 17-31.
44. Jorgensen, W.L.; Ruiz-Caro, J.; Tirado-Rives, J.; Basavapathruni, A.; Anderson, K.S.; Hamilton, A.D. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett., 2006, 16, 663-7.
45. Ruiz-Caro, J.; Basavapathruni, A.; Kim, J.T.; Bailey, C.M.; Wang, L.; Anderson, K.S.; Hamilton, A.D.; Jorgensen, W.L. Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett., 2006, 16, 668-71.
46. Thakur, V.V.; Kim, J.T.; Hamilton, A.D.; Bailey, C.M.; Domaoal, R.A.; Wang, L.; Anderson, K.S.; Jorgensen, W.L. Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett., 2006, 16, 5664-7.
47. Kim, J.T.; Hamilton, A.D.; Bailey, C.M.; Domaoal, R.A.; Wang, L.; Anderson, K.S.; Jorgensen, W.L. FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Am. Chem. Soc., 2006, 128, 15372-3.
48. Barreiro, G.; Kim, J.T.; Guimarães, C.R.; Bailey, C.M.; Domaoal, R.A.; Wang, L.; Anderson, K.S.; Jorgensen, W.L. From docking false-positive to active anti-HIV agent. J. Med. Chem., 2007, 50, 5324-9.
49. Barreiro, G.; Guimarẽs, C.R.; Tubert-Brohman, I.; Lyons, T.M.; Tirado-Rives, J.; Jorgensen, W.L. Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring. J. Chem. Inf. Model, 2007, 47, 2416-28.
50. Zeevaart, J.G.; Wang, L.; Thakur, V.V.; Leung, C.S.; Tirado-Rives, J.; Bailey, C.M.; Domaoal, R.A.; Anderson, K.S.; Jorgensen, W.L. Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. J. Am. Chem. Soc., 2008, 130, 9492-9.
51. Nawrozkij, M.B.; Rotili, D.; Tarantino, D.; Botta, G.; Eremiychuk, A.S.; Musmuca, I.; Ragno, R.; Samuele, A.; Zanoli, S.; Armand-Ugón, M.; Clotet-Codina, I.; Novakov, I.A.; Orlinson, B.S.; Maga, G.; Esté, J.A.; Artico, M.; Mai, A. 5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl) pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile. J. Med. Chem., 2008, 51, 4641-52.
52. Radi, M.; Maga, G.; Alongi, M.; Angeli, L.; Samuele, A.; Zanoli, S.; Bellucci, L.; Tafi, A.; Casaluce, G.; Giorgi, G.; Armand-Ugon, M.; Gonzalez, E.; Esté, J.A.; Baltzinger, M.; Bec, G.; Dumas, P.; Ennifar, E.; Botta, M. Discovery of chiral cyclopropyl dihydroalkylthio-benzyl -oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants. J. Med. Chem., 2009, 52, 840-51.
53. Ji, L.; Chen, F.E.; De Clercq, E,.; Balzarini, J. ; Pannecouque, C. Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem., 2007, 50, 1778-86.
54. Radi, M.; Contemori, L.; Castagnolo, D.; Spinosa, R.; Esté, J.A.; Massa, S.; Botta, M. A versatile route to C-6 arylmethyl-functionalized S-DABO and related analogues. Org. Lett., 2007, 9, 3157-60.
55. Radi, M.; Angeli, L.; Franchi, L.; Contemori, L.; Maga, G.; Samuele, A.; Zanoli, S.; Armand-Ugon, M.; Gonzalez, E.; Llano, A.; Esté, J.A.; Botta, M. Towards novel S-DABOC inhibitors: Synthesis, biological investigation, and molecular modeling studies. Bioorg. Med. Chem. Lett., 2008, 18, 5777-5780.
56. Ripamonti, D.; Maggiolo, F. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Curr. Opin. Investig. Drugs, 2008, 9, 899-912.
57. Qin, H.; Liu, C.; Zhang, J.; Guo, Y.; Zhang, S.; Zhang, Z.; Wang, X.; Zhang, L.; Liu, J. Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino- 6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2009, In Press, Accepted Manuscript, doi:10.1016/j.bmcl.2009.04.051
58. Radi, M.; Falciani, C.; Contemori, L.; Petricci, E.; Maga, G.; Samuele, A.; Zanoli, S.; Terrazas, M.; Castria, M.; Togninelli, A.; Esté, J.A.; Clotet-Codina, I.; Armand-Ugón, M.; Botta, M. A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs. ChemMedChem. 2008, 3, 573-93.
59. Barreca, M.L.; Rao, A.; De Luca, L.; Iraci, N.; Monforte, A.M.; Maga, G.; De Clercq, E.; Pannecouque, C.; Balzarini, J.; Chimirri, A. Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg. Med. Chem. Lett., 2007, 17, 1956-60.
60. Krajewski, K.; Zhang, Y.; Parrish, D.; Deschamps, J.; Roller, P.P.; Pathak, V.K. New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: Synthesis, resolution, and inhibitory activity. Bioorg. Med. Chem. Lett., 2006, 16, 3034-8.
61. Zhang, Z.; Walker, M.; Xu, W.; Shim, J.H.; Girardet, J.L.; Hamatake, R.K.; Hong, Z. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 2006, 50, 2772-81.
62. Jones, L.H.; Allan, G.; Barba, O.; Burt, C.; Corbau, R.; Dupont, T.; Kno.. chel, T.; Irving, S.; Middleton, D.S.; Mowbray, C.E.; Perros, M.; Ringrose, H.; Swain, N.A.; Webster, R.; Westby, M.; Phillips, C. Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays (dagger). J. Med. Chem., 2009 Jan 28. (Epub ahead of print).
63. Zhou, Z.; Madrid, M.; Evanseck, J.D.; Madura, J.D. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. J. Am. Chem. Soc., 2005, 127, 17253-60.
64. Teague, S.J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov., 2003, 2, 527-41.
65. Das, K.; Lewi, P.J.; Hughes, S.H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol., 2005, 88, 209-31.
66. Wang, Z.; Bennett, E.M.; Wilson, D.J.; Salomon, C.; Vince, R. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. J. Med. Chem., 2007, 50, 3416-9.
67. Wang, Z.; Vince, R. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. Bioorg. Med. Chem. Lett., 2008, 1118, 1293-1296
68. Wang, Z.; Vince, R. Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine. Bioorg. Med. Chem., 2008, 16, 3587-95.